HQ Team
December 16, 2022: Jazz Pharmaceuticals Plc announced its plant-derived cannabis epilepsy medicine had improved patients’ seizure and non-seizure outcomes.
Epidiolex, a pharmaceutical formulation of highly purified cannabidiol, is the first and only prescription, plant-derived, cannabis-based medicine approved by the U.S. Food and Drug Administration.
It may be used to treat seizures associated with Lennox-Gastaut Syndrome, Dravet Syndrome, and tuberous sclerosis complex in patients aged one year and older.
“At Jazz, we strive to continually deepen our understanding of the benefits of Epidiolex across the patient experience. The data from the BECOME Caregiver Survey provide important insights into the reported effects of Epidiolex on both seizure and non-seizure outcomes,” said Kelvin Tan, chief medical officer of Dublin-based Jazz Pharmaceuticals.
BECOME stands for behaviour, cognition, and more with Epidiolex.
“These data expand our understanding of the multifaceted experience of people living with epilepsy and their caregivers and could ultimately refine the Epidiolex treatment paradigm across age groups. The BECOME study ensures that patients and caregivers lived experience is front and centre in clinical research,” Tan said.
Lead author and investigator Timothy B. Saurer, Medical Affairs Director of Jazz Pharmaceuticals, said:” We look forward to additional insights from the BECOME survey as we work to further characterize the specific effects of Epidiolex in both adult and pediatric patients living with rare, treatment-resistant epilepsy conditions.”
The most common side effects of Epidiolex include: sleepiness, decreased appetite, diarrhoea, increased liver enzymes, feeling very tired or weak, rash, sleep problems, fever, vomiting and infections.
